Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Nichols

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
American Journal of Respiratory and Critical Care Medicine|May 8, 2010
Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosisJerry A Nick, Cathy S Chacon, Sara J Brayshaw, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
American Journal of Respiratory and Critical Care Medicine|May 8, 2010
Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosisJerry A Nick, Cathy S Chacon, Sara J Brayshaw, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
Pageof 7